A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

BACKGROUND: Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open-label trial showed a 6-month pegloticase + methotrexate co-therapy responder rate of 79%, compared to an established 42% pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Botson, John K., Tesser, John R. P., Bennett, Ralph, Kenney, Howard M., Peloso, Paul M., Obermeyer, Katie, Song, Yang, LaMoreaux, Brian, Zhao, Lin, Xin, Yan, Chamberlain, Jason, Ramanathan, Srini, Weinblatt, Michael E., Peterson, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404640/
https://www.ncbi.nlm.nih.gov/pubmed/36008814
http://dx.doi.org/10.1186/s13075-022-02865-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404640/
https://www.ncbi.nlm.nih.gov/pubmed/36008814
http://dx.doi.org/10.1186/s13075-022-02865-z

Ejemplares similares